Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer
Figure 3
Kaplan Meier Analysis of overall survival. Favorable CTCs are indicated with 1 through 4 and Unfavorable CTCs with 5 through 8. (a) Median overall survival of MBC patients with Favorable CTC after 3–5 Weeks (1) (), 6–8 Weeks (2) (), 9–14 Weeks (3) () and 15–20 Weeks (4) () of treatment median was 21.7, 19.1, 20.8, and 20.1 months, respectively. Median overall survival of MBC patients with Unfavorable CTC after 3–5 Weeks (5) (), 6–8 Weeks (6) () 9–14 Weeks (7) (), and 15–20 Weeks (8) () of treatment was 6.2, 6.3, 6.4, and 11.3 months, respectively. (b) Median overall survival of MCRC patients with Favorable CTC after 1–2 Weeks (1) (), 3–5 Weeks (2) (), 6–12 Weeks (3) (), and 13–20 Weeks (4) () of treatment was 15.7, 16.4, 15.8, and 14.6 months, respectively. Median overall survival of MCRC patients with Unfavorable CTC after 1–2 Weeks (5) () 3–5 Weeks (6) (), 6–12 Weeks (7) (), and 13–20 Weeks (8) () of treatment median was 6.1, 4.4, 3.3, and 3.3 months, respectively. (c) Median overall survival of MPC patients with Favorable CTC after 2–5 Weeks (1) (), 6–8 Weeks (2) (), 9–12 Weeks (3) (), and 13–20 Weeks (4) () of treatment median was 20.7, 19.9, 19.6, and 19.8 months, respectively. Median overall survival of MPC patients with Unfavorable CTC after 2–5 Weeks (5) (), 6–8 Weeks (6) (), 9–12 Weeks (7) (), and 13–20 Weeks (8) () of treatment was 9.5, 8.5, 7.6, and 6.7 months, respectively. The cutoff value between favorable and unfavorable CTC was 5 CTC/7.5 mL blood for breast and prostate cancer and 3 CTC/7.5 mL blood for prostate cancer.
